Beam Therapeutics | Company Profile - Revenue, Headcount, Tech Stack, Contacts

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in precision genetic medicines through advanced gene editing technologies. Founded in 2017 by scientists from the Broad Institute of MIT and Harvard, the company focuses on CRISPR base editing and prime editing to develop therapies for serious diseases. The company went public in February 2020, raising $180 million, and has since built a fully integrated platform combining gene editing, delivery technologies, and internal manufacturing capabilities.

Its proprietary base editing technology enables precise DNA modifications without double-strand breaks, offering targeted genomic changes for genetic disorders. Programs span gene therapy, precision medicines, hematology, immunology, and cell therapy. Revenue comes primarily via licensing and collaboration agreements with partners such as Pfizer and Lilly. Beam is dedicated to delivering lifelong cures for genetic diseases through cutting-edge research and innovation.